COMPOSITIONS COMPRISING BACTERIAL STRAINS
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
1 . A composition comprising the bacterium deposited under accession number NCIMB 42380 or a biotype thereof, for use in a method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway.
2 . The composition of claim 1 , wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of asthma, such as allergic asthma or neutrophilic asthma; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; multiple sclerosis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; chronic obstructive pulmonary disease (COPD); cancer, such as breast cancer, colon cancer, lung cancer or ovarian cancer; uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection.
3 . The composition of claim 2 , wherein the composition is for use in in a method of treating or preventing asthma, such as neutrophilic asthma or allergic asthma.
4 . The composition of claim 3 , wherein the composition is for use in a method of reducing neutrophilia or eosinophilia in the treatment of asthma.
5 . The composition of claim 2 , wherein the composition is for use in in a method of treating or preventing rheumatoid arthritis.
6 . The composition of claim 5 , wherein the composition is for use in a method of reducing joint swelling in rheumatoid arthritis.
7 . The composition of claim 2 , wherein the composition is for use in in a method of treating or preventing multiple sclerosis.
8 . The composition of claim 7 , wherein the composition is for use in a method of reducing disease incidence or disease severity.
9 . The composition of claim 2 , wherein the composition is for use in a method of treating or preventing cancer, such as lung cancer, breast cancer or liver cancer.
10 . The composition of claim 9 , wherein the composition is for use in a method of reducing tumour size, reducing tumour growth, preventing metastasis or preventing angiogenesis.
11 . The composition of claim 2 , wherein the composition is for use in a method of treating or preventing uveitis.
12 . The composition of claim 11 , wherein the composition is for use in a method of reducing or preventing retinal damage in uveitis.
13 . The composition of any preceding claim, wherein the composition is for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of a disease or condition mediated by IL-17 or the Th17 pathway.
14 . The composition of any preceding claim, wherein the composition is for use in a patient with elevated IL-17 levels or Th17 cells.
15 . The composition of any preceding claim, wherein the biotype has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of the bacterium deposited under accession number NCIMB 42380.
16 . The composition of any of claims 1 - 14 , wherein the biotype has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1.
17 . The composition of any preceding claim, wherein the composition is for oral administration.
18 . The composition of any preceding claim, wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers.
19 . The composition of any preceding claim, wherein the bacterial strain is lyophilised.
20 . A food product comprising the composition of any preceding claim, for the use of any preceding claim.
21 . A vaccine composition comprising the composition of any preceding claim, for the use of any preceding claim.
22 . A method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway, comprising administering a composition comprising the bacterium deposited under accession number NCIMB 42380 or a biotype thereof.
23 . A cell of the bacterium deposited under accession number NCIMB 42380, or a derivative thereof.
24 . A composition comprising the cell of claim 23 .
25 . The composition of claim 24 , comprising a pharmaceutically acceptable carrier or excipient.
26 . A biologically pure culture of the bacterium deposited under accession number NCIMB 42380, or a derivative thereof.
27 . A cell of the bacterium deposited under accession number NCIMB 42380, or a derivative thereof, for use in therapy.
28 . The cell of claim 27 , wherein the cell is for use in a method defined in any of claims 1 - 14 .